Challenges for the oral delivery of macromolecules

The rapid integration of new technologies by the pharmaceutical industry has resulted in numerous breakthroughs in the discovery, development and manufacturing of pharmaceutical products. In particular, the commercial-scale production of high-purity recombinant proteins has resulted in important additions to treatment options for many large therapeutic areas. In addition to proteins, other macromolecules, such as the animal-derived mucopolysacharide heparins, have also seen dramatic growth as injectable pharmaceutical products. To date, macromolecules have been limited as therapeutics by the fact that they cannot be orally delivered. This article will address the current status and future possibilities of oral macromolecular drug delivery.

[1]  G. Hardee,et al.  Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs. , 2002, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[2]  G. Russell-Jones,et al.  Vitamin B12-mediated transport of nanoparticles across Caco-2 cells. , 1999, International journal of pharmaceutics.

[3]  D. Meyer,et al.  1986: A year of new insights into how proteins cross membranes , 1986 .

[4]  B. Stoll,et al.  A mechanistic analysis of carrier-mediated oral delivery of protein therapeutics. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[5]  G. Giménez-Gallego,et al.  A partly folded state of acidic fibroblast growth factor at low pH. , 1997, European journal of biochemistry.

[6]  M. Rafiee-Tehrani,et al.  Effects of superporous hydrogels on paracellular drug permeability and cytotoxicity studies in Caco-2 cell monolayers. , 2002, International journal of pharmaceutics.

[7]  Y. Chien,et al.  Systemic delivery of peptides and proteins across absorptive mucosae. , 1996, Critical reviews in therapeutic drug carrier systems.

[8]  S. Frokjaer,et al.  Dipeptide model prodrugs for the intestinal oligopeptide transporter. Affinity for and transport via hPepT1 in the human intestinal Caco-2 cell line. , 2001, Journal of controlled release : official journal of the Controlled Release Society.

[9]  S. Clement,et al.  Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. , 2002, Diabetes technology & therapeutics.

[10]  P. Vierling,et al.  Transepithelial Transport of Prodrugs of the HIV Protease Inhibitors Saquinavir, Indinavir, and Nelfinavir Across Caco-2 Cell Monolayers , 2002, Pharmaceutical Research.

[11]  Dmitry Malkov,et al.  Pathway of Oral Absorption of Heparin with Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate , 2002, Pharmaceutical Research.

[12]  I. Rubio-Aliaga,et al.  Mammalian peptide transporters as targets for drug delivery. , 2002, Trends in pharmacological sciences.

[13]  A. Bernkop‐Schnürch The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[14]  G. Russell-Jones,et al.  Vitamin B12 mediated oral delivery systems for granulocyte-colony stimulating factor and erythropoietin. , 1995, Bioconjugate chemistry.

[15]  C. Porter,et al.  In vitro assessment of oral lipid based formulations. , 2001, Advanced drug delivery reviews.

[16]  M. Khan,et al.  Oral delivery of proteins: progress and prognostication. , 2002, Critical reviews in therapeutic drug carrier systems.

[17]  M. Mihic,et al.  The evolving role of oral insulin in the treatment of diabetes using a novel RapidMist™ System , 2002, Diabetes/metabolism research and reviews.

[18]  T. Fujita,et al.  Modulation of intestinal permeability by nitric oxide donors: implications in intestinal delivery of poorly absorbable drugs. , 2001, The Journal of pharmacology and experimental therapeutics.

[19]  A. Yamamoto,et al.  Improvement of Large Intestinal Absorption of Insulin by Chemical Modification with Palmitic Acid in Rats , 1992, The Journal of pharmacy and pharmacology.

[20]  Nicholas A Peppas,et al.  pH‐Sensitive Hydrogels as Gastrointestinal Tract Absorption Enhancers: Transport Mechanisms of Salmon Calcitonin and Other Model Molecules Using the Caco‐2 Cell Model , 2002, Biotechnology progress.

[21]  W. Curatolo,et al.  C) Means to enhance penetration , 1992 .

[22]  Patricia W. Finn,et al.  Receptor-mediated Immunoglobulin G Transport Across Mucosal Barriers in Adult Life , 2002, The Journal of experimental medicine.

[23]  Donald E. Chickering,et al.  Biologically erodable microspheres as potential oral drug delivery systems , 1997, Nature.

[24]  U. Kompella,et al.  Delivery systems for penetration enhancement of peptide and protein drugs: design considerations. , 2001, Advanced drug delivery reviews.

[25]  David J Brayden,et al.  Heparin Absorption Across the Intestine: Effects of Sodium N-[8-(2-Hydroxybenzoyl)Amino]Caprylate in Rat In Situ Intestinal Instillations and in Caco-2 Monolayers , 1997, Pharmaceutical Research.

[26]  H. Junginger,et al.  Oral drug absorption enhancement by chitosan and its derivatives. , 2001, Advanced drug delivery reviews.

[27]  T. Kissel,et al.  Biodegradable nanoparticles for oral delivery of peptides: is there a role for polymers to affect mucosal uptake? , 2000, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[28]  A. Yamamoto,et al.  Improvement of Intestinal Absorption of Thyrotropin‐releasing Hormone by Chemical Modification with Lauric Acid , 1992, The Journal of pharmacy and pharmacology.

[29]  P. Swaan Recent Advances in Intestinal Macromolecular Drug Delivery via Receptor-Mediated Transport Pathways , 1998, Pharmaceutical Research.

[30]  J. Robinson,et al.  Transcellular and Lipophilic Complex-Enhanced Intestinal Absorption of Human Growth Hormone , 1999, Pharmaceutical Research.

[31]  John A. Michon,et al.  Design considerations , 1993, Generic Intelligent Driver Support.

[32]  G. Russell-Jones Use of vitamin B12 conjugates to deliver protein drugs by the oral route. , 1998, Critical reviews in therapeutic drug carrier systems.

[33]  J. Remon,et al.  Influence of multiple nasal administrations of bioadhesive powders on the insulin bioavailability. , 2003, International journal of pharmaceutics.

[34]  D. Thakker,et al.  Enhancing paracellular permeability by modulating epithelial tight junctions. , 2000, Pharmaceutical science & technology today.

[35]  C. Page,et al.  Novel drug development opportunities for heparin , 2002, Nature Reviews Drug Discovery.

[36]  J. Woodley Enzymatic barriers for GI peptide and protein delivery. , 1994, Critical reviews in therapeutic drug carrier systems.

[37]  G. FitzGerald,et al.  Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. , 1998, Circulation.

[38]  T. Steitz,et al.  The spontaneous insertion of proteins into and across membranes: The helical hairpin hypothesis , 1981, Cell.

[39]  D. Lasič Novel applications of liposomes. , 1998, Trends in biotechnology.

[40]  T. Fujita,et al.  Development of Novel Lipophilic Derivatives of DADLE (Leucine Enkephalin Analogue): Intestinal Permeability Characteristics of DADLE Derivatives in Rats , 2000, Pharmaceutical Research.

[41]  Ho-Chul Shin,et al.  Conjugation of Low-Molecular-Weight Heparin and Deoxycholic Acid for the Development of a New Oral Anticoagulant Agent , 2001, Circulation.

[42]  T. Morimoto,et al.  Mechanisms for the incorporation of proteins in membranes and organelles , 1982, The Journal of cell biology.

[43]  J. McDonough,et al.  Oral Delivery of Biologically Active Parathyroid Hormone , 2001, Pharmaceutical Research.

[44]  J. Lakey,et al.  A 'molten-globule' membrane-insertion intermediate of the pore-forming domain of colicin A , 1991, Nature.

[45]  I. Gómez-Orellana,et al.  Advances in the oral delivery of proteins , 1998 .

[46]  Ronald W. Barrett,et al.  Small Peptides as Potent Mimetics of the Protein Hormone Erythropoietin , 1996, Science.

[47]  N. Utoguchi,et al.  Absorption Enhancement of a Protein Drug by Nitric Oxide Donor: Effect on Nasal Absorption of Human Granulocyte Colony-Stimulating Factor , 2000, Journal of drug targeting.

[48]  G. Flynn,et al.  Absorption of Polyethylene Glycols 600 Through 2000: The Molecular Weight Dependence of Gastrointestinal and Nasal Absorption , 1990, Pharmaceutical Research.

[49]  G Folkers,et al.  Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[50]  H Lennernäs,et al.  Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. , 1998, Journal of medicinal chemistry.

[51]  D. Baccanari,et al.  Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. , 1997, Science.

[52]  T. Mayumi,et al.  Improvement of intestinal absorption of macromolecules by nitric oxide donor. , 2000, Journal of pharmaceutical sciences.

[53]  T. Fujita,et al.  Degradation of Insulin and Calcitonin and Their Protection by Various Protease Inhibitors in Rat Caecal Contents: Implications in Peptide Delivery to the Colon , 1997, The Journal of pharmacy and pharmacology.

[54]  J. Robinson,et al.  Partially unfolded proteins efficiently penetrate cell membranes--implications for oral drug delivery. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[55]  A. Bernkop‐Schnürch,et al.  Multifunctional matrices for oral peptide delivery. , 2001, Critical reviews in therapeutic drug carrier systems.

[56]  K. Hillgren,et al.  Enhanced transepithelial transport of peptides by conjugation to cholic acid. , 1997, Bioconjugate chemistry.

[57]  P. Sinko,et al.  Oral absorption of the HIV protease inhibitors: a current update. , 1999, Advanced drug delivery reviews.

[58]  A. Fasano,et al.  Modulation of intestinal tight junctions by Zonula occludens toxin permits enteral administration of insulin and other macromolecules in an animal model. , 1997, The Journal of clinical investigation.

[59]  T. Fujita,et al.  Absorption characteristics of chemically modified-insulin derivatives with various fatty acids in the small and large intestine. , 1995, Journal of pharmaceutical sciences.

[60]  A. M. Dyer,et al.  Nasal Delivery of Insulin Using Novel Chitosan Based Formulations: A Comparative Study in Two Animal Models Between Simple Chitosan Formulations and Chitosan Nanoparticles , 2002, Pharmaceutical Research.

[61]  C. Porter Drug delivery to the lymphatic system. , 1997, Critical reviews in therapeutic drug carrier systems.

[62]  A. Rubinstein Approaches and opportunities in colon-specific drug delivery. , 1995, Critical reviews in therapeutic drug carrier systems.

[63]  P. Daddona,et al.  Enhancement of intestinal model compound transport by DS-1, a modified Quillaja saponin. , 1998, Journal of pharmaceutical sciences.

[64]  M. Kipnes,et al.  Control of postprandial plasma glucose by an oral insulin product (HIM2) in patients with type 2 diabetes. , 2003, Diabetes care.

[65]  G. Amidon,et al.  Drug transport and targeting. Intestinal transport. , 1999, Pharmaceutical biotechnology.

[66]  H. J. Lee,et al.  Protein drug oral delivery: The recent progress , 2002, Archives of pharmacal research.

[67]  K. Uemura,et al.  Enhanced permeability of tetragastrin across the rat intestinal membrane and its reduced degradation by acylation with various fatty acids. , 1994, The Journal of pharmacology and experimental therapeutics.

[68]  Robert C. Wolpert,et al.  A Review of the , 1985 .

[69]  J. Fix Strategies for delivery of peptides utilizing absorption-enhancing agents. , 1996, Journal of pharmaceutical sciences.

[70]  Y. Chien,et al.  Novel methods of insulin delivery: an update. , 1998, Critical reviews in therapeutic drug carrier systems.

[71]  Jeffrey,et al.  Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies. , 1997, Advanced drug delivery reviews.

[72]  T. Buclin,et al.  Bioavailability and Biological Efficacy of a New Oral Formulation of Salmon Calcitonin in Healthy Volunteers , 2002, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[73]  W. Kramer,et al.  Intestinal absorption of bile acids: paradoxical behaviour of the 14 kDa ileal lipid-binding protein in differential photoaffinity labelling. , 1998, The Biochemical journal.

[74]  R. Panchagnula,et al.  Peroral route: an opportunity for protein and peptide drug delivery. , 2001, Chemical reviews.

[75]  H Lennernäs,et al.  Human intestinal permeability. , 1998, Journal of pharmaceutical sciences.

[76]  A. Daugherty,et al.  Regulation of the intestinal epithelial paracellular barrier. , 1999, Pharmaceutical science & technology today.

[77]  T. Clackson,et al.  A hot spot of binding energy in a hormone-receptor interface , 1995, Science.

[78]  J. Madara Modulation of tight junctional permeability. , 2000, Advanced drug delivery reviews.

[79]  G. Mooter,et al.  Oral colon-specific drug delivery: a review , 1995 .

[80]  N Hussain,et al.  Transcytosis of nanoparticle and dendrimer delivery systems: evolving vistas. , 2001, Advanced drug delivery reviews.

[81]  K. Johnson An Update. , 1984, Journal of food protection.

[82]  T. Yoshikawa,et al.  Oral Delivery of Antigens in Liposomes with Some Lipid Compositions Modulates Oral Tolerance to the Antigens , 2002, Microbiology and immunology.

[83]  V. H. Lee,et al.  Role of Na+ in the asymmetric paracellular transport of 4-phenylazobenzyloxycarbonyl-L-Pro-L-Leu-Gly-L-Pro-D-Arg across rabbit colonic segments and Caco-2 cell monolayers. , 1995, The Journal of pharmacology and experimental therapeutics.

[84]  G. Russell-Jones,et al.  Vitamin B12-mediated uptake of erythropoietin and granulocyte colony stimulating factor in vitro and in vivo , 1996 .

[85]  A. Daugherty,et al.  Transcellular uptake mechanisms of the intestinal epithelial barrier Part one. , 1999, Pharmaceutical science & technology today.